Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,046
  • Shares Outstanding, K 8,821
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -19,990 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.25
  • Price/Sales 36.43
  • Price/Cash Flow N/A
  • Price/Book 2.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +181,736.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.99 +128.14%
on 01/12/26
4.89 -7.19%
on 01/27/26
+2.57 (+130.46%)
since 01/09/26
3-Month
1.81 +150.83%
on 12/29/25
4.89 -7.19%
on 01/27/26
+2.44 (+116.19%)
since 11/11/25
52-Week
1.81 +150.83%
on 12/29/25
4.89 -7.19%
on 01/27/26
+2.03 (+80.88%)
since 02/11/25

Most Recent Stories

More News
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RAPT : 57.72 (-0.03%)
ALGT : 109.33 (-4.38%)
LSTA : 4.54 (unch)
AVO : 13.66 (-0.36%)
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RAPT : 57.72 (-0.03%)
ALGT : 109.33 (-4.38%)
LSTA : 4.54 (unch)
AVO : 13.66 (-0.36%)
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

RAPT : 57.72 (-0.03%)
LSTA : 4.54 (unch)
PEN : 338.26 (-0.21%)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

NEW YORK , Jan. 28, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

NATH : 100.89 (+0.01%)
RAPT : 57.72 (-0.03%)
LSTA : 4.54 (unch)
PEN : 338.26 (-0.21%)
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 4.54 (unch)
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Shareholders should contact the firm as there may be limited time to enforce your rights.

LSTA : 4.54 (unch)
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium...

LSTA : 4.54 (unch)
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Data rich period continues to support certepetide’s broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug...

LSTA : 4.54 (unch)
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 4.54 (unch)
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 4.54 (unch)

Business Summary

Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The company's principal product candidate includes LSTA1. Lisata Therapeutics Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 4.58
2nd Resistance Point 4.57
1st Resistance Point 4.55
Last Price 4.54
1st Support Level 4.52
2nd Support Level 4.51
3rd Support Level 4.49

See More

52-Week High 4.89
Last Price 4.54
Fibonacci 61.8% 3.71
Fibonacci 50% 3.35
Fibonacci 38.2% 2.99
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar